Recently, the raging of the new crown epidemic has caused a lot of inconvenience to the society. In the case of the hospital ban and the isolation of the subjects, the first-phase registration clinical trial of the LY007 project of Longyao Biology was conducted in PI Director Zhao Weilai, SubI Teacher Yan Zixun, Wang Xueqin and others. With the joint efforts of team members, on April 7, 2022, the first patient's cell reinfusion was successfully completed at Ruijin Hospital Affiliated to Shanghai Jiaotong University. The reinfusion process was generally smooth, and the subjects were in good condition after the reinfusion.
As a Longyao person, we always insist on the safety of patients' life as the first consideration. In the following observation period, we will continue to work hard, starting from the maximum benefit of patients, and make every effort to ensure the smooth progress of the trial.
About Products
LY007 cell injection is a CD20-targeting chimeric antigen receptor autologous T cell (CAR-T) injection that is genetically modified using lentiviral vector. The co-stimulatory signaling receptor OX40, experiments have shown that this structure can reduce T cell exhaustion, enhance the proliferation and killing ability of CAR-T cells, and make it release more effectors, thereby improving CAR in terms of safety and efficacy. -T performance.
About clinical trials
On January 21, 2021, Longyao Bio received the approval notice from the State Drug Administration for the approval of the clinical trial of the cell injection named LY007, and on January 25, 2022, and January 27, respectively, in Ruijin Hospital The kick-off meeting was successfully held with Jiangsu Provincial People's Hospital. The project was co-chaired by Vice President Zhao Weili of Ruijin Hospital and Director Li Jianyong of the Department of Hematology of Jiangsu Provincial People's Hospital. On March 1, 2022, the project officially enrolled the first patient in Shanghai Ruijin Hospital.
About Longyao Bio
Founded in 2013, Longyao Bio is located in Jing'an District, Shanghai. It is an independent innovation enterprise dedicated to the research and development of tumor immune cell drugs. The controlling shareholder is China Biotechnology Services Holdings Limited (8037.HK), a Hong Kong-listed company. Bio has the first and only CD20-targeted CAR-T product approved for clinical registration in China, and other products cover hematological tumors, solid tumors and other fields.